Data as an asset – what does this mean to you?

Social media frequently depict data as the new oil. Whilst Industry 4.0 is data centric, in the sense that it promotes a data driven “piloting of the vessel”, quotes like the above should be interrogated or at least taken with a pinch of salt. There is no doubt that data constitutes an asset but the fundamental value of this asset, to invoke a stock market jargon, remains not well understood.  Biopharma has adopted the mentality that it sits on a pile of cash and has ostensibly embarked on a journey to capitalize on its data.  However, although the market provides an excellent mechanism for evaluating an asset, the strategy of most corporations is paradoxical in that it does not aim to quantify demand but rather to tailor it to its traditional views. This talk will attempt to explore the data market by uncovering not only conventional ways to capitalize on data but also tapping onto drastically unconventional proposals that throw biopharma out of its comfort zone. The results of this exercise corroborate the suspicion that realizing the fundamental value of data as an asset requires revising the traditional ways of working.
Presented by Christos Varsakelis, Team Lead Artificial Intelligence/Machine Learning at The Janssen Pharmaceutical Companies of Johnson & Johnson

Christos Varsakelis leads the AI/ML team for Drug Discovery in the Janssen Pharmaceutical Companies aiming at the acceleration of development timelines and increase of probability of technical success. Prior joining Janssen, Christos was a Senior Manager of Global Analytics & Innovation in GSK Vaccines focusing on in silico Bioprocess development. Besides working in the pharmaceutical industry, Christos has an accumulated professional experience that spans across Geoconsulting, the stock market and the chemical industry. Christos is in hold of a Ph.D. in fluid mechanics in UCLouvain in Belgium. He is also in hold of a B.A. in Mathematics from the Aristotle University of Thessaloniki, Greece and an M.Sc. in Applied Mathematics from the ETH Zurich, Switzerland. His moto is innovation = cash.
Followed by Klaus Mauch, CEO at Yokogawa Insilico Biotechnology GmbH

Klaus Mauch is one of Insilico’s co-founders and became managing director in 2004 and CEO in 2006. In his previous role as CTO, he was responsible for the design and development of Insilico’s modeling and simulation platform where he established novel methods for the computer-aided construction of cellular networks. Before that, he gained extensive experience in metabolic engineering and applied systems biology as a group leader at the Institute of Biochemical Engineering, University of Stuttgart. He was awarded a Master’s degree in Chemical Engineering by the Technical University of Karlsruhe, Germany. Klaus is a member of the Advisory Board of the Division Systems Biology and Synthetic Biology of DECHEMA, a board member of the Industrial Association White Biotechnology (IWBio), and a board member of the Association of German Biotechnology Companies (VBU).
Sponsored by Yokogawa Insilico Biotechnology GmbH
 

Yokogawa Insilico Biotechnology GmbH develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Ground breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Yokogawa Insilico Biotechnology GmbH, based in Stuttgart, Germany, is a subsidiary of Yokogawa Corporate Electric Corporation, based in Tokyo, Japan.